Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Just published.
Pleased to share our work on RET‑positive lung cancer published in American Society of Clinical Oncology (ASCO) – Journal Of Clinical Oncology, Final Efficacy and Safety Data from the Phase I/II ARROW Study of Pralsetinib in Advanced RET Fusion–Positive NSCLC.
Still remember the very first RET+ patient in the universe enrolled on this drug. Knew this baby will graduate and this molecule was going to deliver․
Kudos to the global collaborators and amazing colleagues who pushed this all the way to the finish line.”
Title: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RETFusion–Positive Non–Small Cell Lung Cancer
Authors: Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, Daniel W. Bowles, Robert C. Doebele, Aaron S. Mansfield, Christina S. Baik, Gilberto de Lima Lopes, Luis Paz-Ares, Matthew H. Taylor, Daniel S. W. Tan, Guzman Alonso, Shirish M. Gadgeel, Gregory P. Kalemkerian, Sai-Hong Ignatius Ou, Anthonie J. van der Wekken, Carlos R. Becerra, Makenzi Evangelist, Frank Griesinger, Stephen V. Liu, Yanyan Lou, Julien Mazières, Jason M. Melear, Mohit Narang, Ashish Saxena, Michael Thomas, Sophia Wang, Amber Thomassen, Dae Ho Lee, Dong-Wan Kim, Justin F. Gainor
Other articles featuring Vivek Subbiah on OncoDaily.